BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Generic Business Image

BioStock: PHIs CEO eyes new business opportunities

BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Two images showing cell culturing of today and tomorrow

Aktiespararna: PHIs teknik är nu redo att förvandla regenerativ medicin till framtidens sjukvård

PHI går i spetsen för nästa generation av cell-analys instrumentering, och gör nu en företrädesemission för att kunna fortsätta expandera inom klinisk tillämpning. Läs hela intervjun på Aktiespararna.

January 7, 2020

CEO interview in BioStock

In the article published today by BioStock, the company’s CEO Peter Egelberg comments on the developments during the past autumn.

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.

1…5 678